- Report
- February 2025
- 200 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Report
- January 2025
- 175 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1850EUR$2,000USD£1,556GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2775EUR$3,000USD£2,334GBP
- Report
- October 2022
- 270 Pages
Global
From €3469EUR$3,750USD£2,917GBP
- Report
- May 2024
- 133 Pages
Global
From €6012EUR$6,499USD£5,056GBP
- Report
- June 2023
- 118 Pages
Global
From €4163EUR$4,500USD£3,501GBP
- Report
- May 2024
- 160 Pages
Global
From €4578EUR$4,949USD£3,850GBP
- Drug Pipelines
- April 2024
- 202 Pages
Global
From €7354EUR$7,950USD£6,185GBP
- Report
- August 2022
- 118 Pages
Global
From €4394EUR$4,750USD£3,695GBP
- Report
- February 2023
- 135 Pages
Africa
From €3469EUR$3,750USD£2,917GBP
- Report
- July 2023
- 200 Pages
Global
From €4163EUR$4,500USD£3,501GBP
- Report
- July 2023
- 218 Pages
Global
From €4163EUR$4,500USD£3,501GBP
- Report
- May 2025
- 50 Pages
Global
From €2451EUR$2,650USD£2,062GBP

Leflunomide is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. It works by blocking the production of certain proteins that cause inflammation and joint damage. It is usually taken in pill form, but can also be administered as an injection.
Leflunomide is a relatively new drug, having been approved by the US Food and Drug Administration in 1998. It is generally well-tolerated, with few side effects. Common side effects include nausea, diarrhea, and headache.
The leflunomide market is growing, as more people are being diagnosed with immune disorders. It is a competitive market, with several companies offering their own versions of the drug. Companies in the leflunomide market include Sanofi, Pfizer, Merck, and AbbVie. Show Less Read more